Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. by Cloughesy, Timothy F et al.
UCSF
UC San Francisco Previously Published Works
Title
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis 


















eScholarship.org Powered by the California Digital Library
University of California
© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
Neuro-Oncology
20(2), 259–267, 2018 | doi:10.1093/neuonc/nox151 | Advance Access date 3 October 2017
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any 
medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
259
Phase II study of cabozantinib in patients with 
progressive glioblastoma: subset analysis of patients 
with prior antiangiogenic therapy
Timothy F. Cloughesy, Jan Drappatz,† John de Groot, Michael D. Prados, David A. Reardon, 
David Schiff, Marc Chamberlain, Tom Mikkelsen, Annick Desjardins, Jerry Ping, Jaymes Holland, 
Ron Weitzman, and Patrick Y. Wen
The Ronald Reagan UCLA Medical Center, Los Angeles, California (T.F.C.); Center for Neuro-Oncology, Dana-Farber/
Brigham & Women’s Cancer Center, Boston, Massachusetts (P.Y.W., J.D.); The University of Texas MD Anderson 
Cancer Center, Houston, Texas (J.dG.); University of California San Francisco, San Francisco, California (M.D.P.); Duke 
University, Durham, North Carolina (D.A.R., A.D.); Neuro-Oncology Center, University of Virginia Health System, 
Charlottesville, Virginia (D.S.); University of Washington, Department of Neurology, Fred Hutchinson Cancer Research 
Center, Seattle, Washington (M.C.); Henry Ford Health System, Detroit, Michigan (T.M.); Exelixis, South San Francisco, 
California (J.P., J.H., R.W.)
Corresponding Author: Timothy F. Cloughesy, MD, The Ronald Reagan UCLA Medical Center, 710 Westwood Plaza, Reed Bldg RM 
1-230, Los Angeles, CA 90095 (tcloughesy@mednet.ucla.edu).
†J.D. current affiliation: University of Pittsburgh Medical Center, Hillman Cancer Centers, UPMC Cancer Pavilion, 
Pittsburgh, Pennsylvania.
Abstract
Background. Cabozantinib is a potent, multitarget inhibitor of MET and vascular endothelial growth factor receptor 
2 (VEGFR2). This open-label, phase II trial evaluated cabozantinib in patients with recurrent or progressive glioblast-
oma (GBM).
Methods. Patients were initially enrolled to a starting cabozantinib dose of 140 mg/day, but the starting dose was 
amended to 100 mg/day because of safety concerns. Treatment continued until disease progression or unacceptable 
toxicity. The primary endpoint was objective response rate, assessed by an independent radiology facility using 
modified Response Assessment in Neuro-Oncology criteria. Additional endpoints included duration of response, 
6-month and median progression-free survival, overall survival, glucocorticoid use, and safety.
Results. Among 222 patients enrolled, 70 had received prior antiangiogenic therapy. Herein, we report results in 
this subset of 70 patients. The objective response rate was 4.3%, and the median duration of response was 4.2 
months. The proportion of patients alive and progression free at 6 months was 8.5%. Median progression-free 
survival was 2.3 months, and median overall survival was 4.6 months. The most common adverse events reported 
in all patients, regardless of dose group, included fatigue (74.3%), diarrhea (47.1%), increased alanine aminotrans-
ferase (37.1%), headache (35.7%), hypertension (35.7%), and nausea (35.7%); overall, 34 (48.6%) patients experi-
enced adverse events that resulted in dose reductions.
Conclusions. Cabozantinib treatment appeared to have modest clinical activity with a 4.3% response rate in 
patients who had received prior antiangiogenic therapy for GBM.
Clinical Trials Registration Number:  NCT00704288 (https://www.clinicaltrials.gov/ct2/show/NCT00704288)
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Glioblastoma (GBM) is a fatal disease that constitutes 
45.6% of brain and CNS malignancies; is more com-
mon in adults, especially males; and peaks between 75 
and 84 years of age.1 Despite current first-line treatment 
options, disease recurrence is high, with approximately 
one-third of patients surviving for 1 year, and <5% remain-
ing alive at 5 years.1 Current treatment options for recurrent 
GBM are limited and may include surgery, reirradiation, 
chemotherapy, tumor treating fields, and bevacizumab.2
GBM tumors are highly vascularized, and therapies that 
inhibit angiogenic signals, such as vascular endothelial 
growth factor (VEGF), have been shown to suppress tumor 
growth in vivo.3 Single-agent bevacizumab is approved in 
the United States for treatment of recurrent GBM based 
on durable objective response rates (ORRs).4 Phase II tri-
als that evaluated bevacizumab in patients with recurrent 
GBM demonstrated median progression-free survival 
(PFS) of approximately 4 months and median overall sur-
vival (OS) in the range of 8 to 9 months.5,6 While bevaci-
zumab is a standard of care for recurrent GBM, the phase 
II Dutch BELOB trial reported 9-month OS rates of 38% for 
bevacizumab, 43% for lomustine, 59% for bevacizumab/
lomustine 90 mg/m2, and 88% for bevacizumab/lomustine 
110 mg/m2 in patients with a first recurrence, suggesting 
that single-agent bevacizumab is not superior to lomustine 
and that the combination warrants further investigation.7 
However, a phase III trial of bevacizumab plus lomustine 
compared with lomustine alone in patients with GBM at 
first recurrence did not show improved OS for the com-
bination compared with lomustine alone: median OS was 
9.1 months versus 8.6 months, respectively.8
Although bevacizumab-based therapy is commonly 
used for treatment of recurrent GBM, prognosis remains 
poor, and patients either do not respond or develop 
treatment-acquired resistance.9 Patients who experience 
disease progression while receiving bevacizumab rarely 
respond to further salvage therapy.9 Currently, there is no 
standard treatment for patients following progression on 
bevacizumab, and other cancers post bevacizumab pro-
gression appear resistant to selective targeting of the VEGF 
pathway. Therapies that target multiple pathways involved 
in GBM pathogenesis are needed.10–13 In vivo and in vitro 
studies have shown that the MET proto-oncogene/hep-
atocyte growth factor (MET/HGF) pathways are important 
mediators in the development of GBM.14–17 In particular, 
high levels of MET are observed in recurrent GBM, and 
MET overexpression is associated with poor response to 
treatment and shorter PFS and median OS.16,18 Preclinical 
data suggest that MET overexpression may be responsible 
for the development of bevacizumab resistance and that 
targeting MET may offer a mechanism to prevent or over-
come resistance.17,19 The receptor tyrosine kinase AXL may 
also be involved in GBM pathogenesis based on preclinical 
studies and has been associated with a poor prognosis in 
patients with GBM.20–23
Cabozantinib is a multitarget tyrosine kinase inhibi-
tor with potent activity against MET and VEGF receptor 2 
(VEGFR2), as well as other kinases that have been impli-
cated in tumor pathobiology (AXL, KIT, RET, TIE2, and 
FLT3).24 In preclinical studies, cabozantinib treatment 
resulted in dose-dependent inhibition of tumor growth in 
breast, lung, and glioma models and decreased tumor and 
endothelial cell proliferation as well as reduced tumor vas-
culature in mouse models.24,25 In a mouse xenograft model 
of human GBM, cabozantinib treatment significantly 
increased median OS compared with the placebo-treated 
control (32 vs 20 days, respectively; P < 0.0001).26
This phase II trial examined the efficacy and safety of 2 
starting doses of cabozantinib (140 mg/day and 100 mg/
day) in 222 patients with progressive or recurrent GBM. 
As molecular changes in disease may contribute to the 
development of resistance to antiangiogenic therapy, we 
conducted separate subgroup analyses for patients based 
on prior antiangiogenic therapy. Here we report the results 
from the subgroup of 70 patients who had received previ-
ous antiangiogenic therapy before study entry. Results for 
patients naive to antiangiogenic therapy are presented in 
the companion article (Wen et al).
Materials and Methods
Patients
Eligible adult patients (≥18 y old) had progressive or 
recurrent GBM that was confirmed by gadolinium (Gd)-
enhanced MRI performed within 14 days of the first dose of 
cabozantinib. Some entry criteria differed among patients 
due to amendments to the protocol (see Supplementary 
material). Patients were required to have received prior 
radiation therapy and temozolomide (for patients enrolled 
at the 100 mg/day dose), and could have also received 
prior VEGF or VEGFR2 inhibitors. Eligible patients had a 
Karnofsky performance status ≥60% and adequate hema-
tologic, renal, and liver function. Patients were excluded 
if they had received prior anticancer therapy within speci-
fied time limits before the first dose of cabozantinib, 
including anticancer therapy within 28 days (including 
Importance of the study
GBM is a common CNS tumor with limited treatment 
options. Antiangiogenic therapy with  bevacizumab, 
a VEGF pathway inhibitor, is a standard of care for 
patients with recurrent disease, and therapies are 
needed for patients who have progressed on this 
treatment. Cabozantinib is an orally bioavailable 
inhibitor of tyrosine kinases including VEGFR2, MET, 
and AXL. The MET pathway has been implicated in 
resistance to bevacizumab therapy and the pathogen-
esis of GBM. The current study reports the results of 
cabozantinib treatment in 70 patients who received 
prior antiangiogenic therapy. Cabozantinib treatment 
showed only modest clinical activity in this patient 
population.








investigational agents and biologic agents except bevaci-
zumab), bevacizumab within 14 days, or mitomycin C or 
nitrosoureas within 42 days. All patients provided informed 
written consent. The protocol was approved by ethics com-
mittees or institutional review boards at each investiga-
tor’s institution. This trial was conducted in accordance 
with the principles of the International Conference on 
Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH) guideline for 
Good Clinical Practice, the World Medical Association 
Declaration of Helsinki, and Title 21 of the United States 
Code of Federal Regulations.
Study Design
This phase II, multicenter, open-label, single-agent study 
evaluated 2 doses of cabozantinib in patients with recur-
rent or progressive GBM in first or second relapse. Patients 
were defined to be enrolled upon receipt of the first dose of 
cabozantinib. Cabozantinib was orally administered once 
daily at a starting dose of 140 mg/day (freebase weight); 
however, because rates of dose reduction and inter-
ruption at 140 mg/day were deemed to be high, and ini-
tial evaluations suggested continued efficacy with doses 
that were reduced to ≤100 mg/day, the starting dose was 
amended to 100 mg/day, and a cohort for initial qualitative 
assessment of the safety and tolerability of the dose was 
added (15 antiangiogenic pretreated patients planned). 
Subsequently, another planned cohort of 45 antiangio-
genic pretreated patients was added at the 100 mg/day 
dose. Patients were treated until disease progression or 
unacceptable toxicity. To manage adverse events (AEs), 
dose could be reduced to 100 mg (for those enrolled at 
140 mg/day), 60 mg, and 40 mg; dose could be reduced 
to lower than 40 mg after consultation with the sponsor. 
Further details of the study design and protocol amend-
ments are provided in the Supplementary material.
Endpoints and Assessments
The primary endpoint was ORR assessed by an inde-
pendent radiology facility (IRF). Key secondary endpoints 
included duration of response, median PFS, OS, and evalu-
ation of glucocorticoid use. Radiographic assessments by 
Gd-contrast MRI were performed at screening and gen-
erally every 6 to 8 weeks thereafter (see Supplementary 
material) and were assessed by the investigator for patient 
management and by the IRF, BioClinica (formerly CoreLab 
Partners [Princeton, NJ]). Tumor response and progression 
were determined by modified Response Assessment in 
Neuro-Oncology (RANO) criteria, which included the com-
ponents of radiographic assessment and glucocorticoid 
use. For implementation in this study, the primary modi-
fications to the RANO criteria for time point responses 
include defining operational conventions for changes in 
glucocorticoid dose and removal of the clinical deterior-
ation component to reduce subjectivity and facilitate IRF 
assessment. Neurologic and clinical status did not contrib-
ute to the response or progression criteria. Tumor assess-
ments for determination of response and progression for 
the primary efficacy analyses were performed by an IRF. 
The minimum lesion size required for measurable disease 
by IRF was 10 mm × 5 mm, reflecting the implementation 
of RANO in this study before publication of the now stand-
ard 10 mm × 10 mm criterion for measurable disease.
Safety and tolerability assessments included monitoring 
AEs, performing standard clinical laboratory tests (including 
hematology, serum chemistry, and urinalysis) and physical 
examinations, and recording electrocardiograms. Severity 
of AEs was assessed by using the National Cancer Institute 
Common Terminology Criteria for Adverse Events, ver-
sion 3. Serious AEs (SAEs) were defined in accordance with 
the ICH Guidelines for Clinical Safety Data Management: 
Definitions and Standards for Expedited Reporting, Topic E2A.
Statistical Analysis
Results for patients who received prior antiangiogenic 
therapy are presented here. Efficacy and safety analyses 
include all such patients enrolled unless otherwise speci-
fied. ORR was the proportion of subjects experiencing 
a confirmed complete or partial response per modified 
RANO criteria at any time during the study. ORR was com-
puted among patients with measurable disease at baseline 
per modified RANO criteria and is presented with 2-sided 
95% CIs. Forty-five patients were planned to evaluate ORR 
in patients with prior antiangiogenic therapy with the fol-
lowing hypotheses (1-sided nominal alpha of 0.1 and power 
of >80%): H0: ORR = 5% and HA: ORR = 15%. The primary 
endpoint was to be analyzed in the last group of patients 
enrolled at the 100 mg/day dose; however, for simplicity, 
all patients who received prior antiangiogenic therapy at 
the 100 mg/day dose were retrospectively combined for 
the efficacy analyses presented here. See Supplementary 
material for more details on the planned analyses.
PFS was calculated as the time from first cabozantinib dose 
to the earlier of documented disease progression per modi-
fied RANO or death from any cause. OS was calculated as the 
time from first cabozantinib dose to death from any cause. 
Median PFS and OS and the associated 2-sided 95% CIs were 
computed using the Kaplan–Meier method. All statistical ana-
lysis was performed using SAS version 8.2 or higher.
Results
Patient Characteristics
Of 222 patients enrolled between June 2008 and June 
2012, 70 (32%) had received ≥1 prior antiangiogenic ther-
apy (Table 1). All subsequent results refer to this sub-
group. Baseline demographics and clinical characteristics 
were similar between the 140 mg/day (n = 12) and 100 mg/
day (n = 58) dose groups (Table 1). The study population 
included mostly male patients (61.4%) with a median age 
of 52.5 years (range, 23–71 y). Overall, the mean number 
of previous anticancer therapies for GBM was 1.8 ± 0.64, 
and 57 patients (81.4%) had received prior bevacizumab. 
The median duration of treatment was 5.7 weeks (range, 
2.0–186.3) in the 140 mg/day group and 7.6 weeks (range, 
1.4–47.9) in the 100 mg/day group.
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Efficacy
All patients (n = 70) had measurable disease at baseline 
as assessed by the IRF and were included in the response 
assessment. The results for ORR did not meet the prede-
fined statistical target for success. Objective responses 
were observed in 3 (4.3%) patients, 33 (47.1%) had stable 
disease, and 18 (25.7%) had progressive disease as best 
response (Table 2). Sixteen patients (23%) were unevalu-
able for tumor response because they did not have an eval-
uable postbaseline tumor assessment. In the 3 patients 
with objective responses, the durations of response were 
1.2, 4.2, and 12.3 months. Among these patients, 1 had 
received prior bevacizumab, and 2 had received other 
antiangiogenic therapies. In patients with ≥1 evaluable 
postbaseline tumor assessment (n = 62), 41 (66%) experi-
enced reductions in tumor volume (Fig. 1). The median fol-
low-up for scans was 1.5 months (range, 0.03–42.6) in the 
140 mg/day group and 1.8 months (range, 0.03–11.0) in the 
100 mg/day group.
Median PFS was 2.3 months overall, 3.3 months in the 
140 mg/day group, and 2.3 months in the 100 mg/day group 
(Fig. 2A). Median OS was 4.6 months overall, 4.1 months 
(95% CI, 1.4–16.7 mo) in the 140  mg/day group, and 
4.6 months (95% CI, 2.9–5.6 mo) in the 100 mg/day group 
(Fig. 2B). At baseline, 33 patients (47.1%) reported systemic 
steroid treatment. Among patients who reported any gluco-
corticoid use at baseline, there was a trend toward decreas-
ing glucocorticoid requirements over time (Fig. 3).
Safety
The most common treatment-emergent AEs included 
fatigue (74.3%), diarrhea (47.1%), increased alanine ami-
notransferase (37.1%), headache (35.7%), hypertension 
(35.7%), nausea (35.7%), constipation (34.3%), increased 
aspartate aminotransferase (30.0%), dysphonia (28.6%), 
increased lactate dehydrogenase (27.1%), proteinuria 
(27.1%), and memory impairment (25.7%) (Table 3).
A total of 34 patients (48.6%) experienced AEs that 
resulted in dose reductions, and the median time to first 
dose reduction was 40.5 days (range, 13–173 days). Dose 
Table 2 Best overall response to treatment by modified RANO criteria 
(per IRF)*





Objective response rate 1 (8.3) 2 (3.4)
Best overall response
  Confirmed partial 
response
1 (8.3) 2 (3.4)
 Stable disease 6 (50.0) 27 (46.6)
 Progressive disease 2 (16.7) 16 (27.6)
  Unevaluable or 
missing**
3 (25.0) 13 (22.4)
Duration of objective 
response, mo
12.3+ 1.2+, 4.2
+Censored at the date of the last tumor assessment.
*All patients with measurable disease at baseline were included in  
the response assessment.
**Unevaluable by modified RANO or no postbaseline tumor 
assessments.
Table 1 Baseline demographics and clinical characteristics
Characteristic Patients, n (%)
140 mg/day (n = 12) 100 mg/day (n = 58)
Age, y
 Median (range) 53 (23–71) 52 (24–68)
Sex
 Male 7 (58.3) 36 (62.1)
 Female 5 (41.7) 22 (37.9)
Race
 White 11 (91.7) 54 (93.1)
 Asian 0 1 (1.7)
  Other/not 
reported
1 (8.3) 3 (5.2)
Karnofsky performance status
 90–100 2 (16.7) 36 (62.1)
 70–80 10 (83.3) 20 (34.5)
 ≤60 0 2 (3.4)
Years since initial diagnosis
 Median (range) 1.07 (0.6–3.5) 1.16 (0.5–7.2)
GBM type
 Primary 11 (91.7) 55 (94.8)
 Secondary 1 (8.3) 3 (5.2)
Prior radiotherapy for GBM
 Yes 11 (91.7) 58 (100.0)
 No 1 (8.3) 0
Prior lines of systemic therapy
 1 3 (25.0) 19 (32.8)
 2 9 (75.0) 35 (60.3)
 ≥3 0 4 (6.9)
Prior antiangiogenic therapy
 Bevacizumab* 9 (75.0) 48 (82.8)
 Other** 3 (25.0) 10 (17.2)
Steroid use at baseline***
 Yes 4 (33.3) 23 (39.7)
 No/unknown 8 (66.7) 35 (60.3)
*Four patients in the 140 mg/day group and 21 patients in the 100 mg/
day group received bevacizumab as part of initial therapy.
**Other antiangiogenic therapies: vandetanib (5 patients); cediranib (4 
patients); CT-322 (2 patients); sunitinib (1 patient); investigational VEGF 
trap (1 patient). Two patients in the 140 mg/day group and 4 patients in 
the 140 mg/day group received other antiangiogenic therapy as initial 
therapy.
***Received at least 7 days of systemic steroids within 30 days  
before the first dose of cabozantinib.








reductions were reported in 5 patients (41.7%) in the 
140 mg/day group and in 29 patients (50.0%) in the 100 mg/
day group. Dose interruptions due to AEs occurred in 29 
patients (41.4%). The median average dose was 123  mg/
day (range, 78.3–140  mg/day) in the 140  mg/day group, 
and 92.6 mg/day (range, 48.1–100 mg/day) in the 100 mg/
day group. Overall, 12 patients (17.1%) discontinued treat-
ment due to AEs: 5 (41.7%) in the 140 mg/day group and 7 
(12.1%) in the 100 mg/day group.
Grade 3 or 4 AEs were reported in 12 (100.0%) and 42 
(72.4%) patients in the 140 mg/day and 100 mg/day groups, 
respectively. Serious AEs were reported in 35 patients 
(50%): 6 patients (50%) in the 140  mg/day group and 29 
patients (50%) in the 100  mg/day group. Common SAEs 
observed in patients treated in either dose group included 
convulsion (5.7%, n =  4), alanine aminotransferase 
increased (4.3%, n =  3), confusional state (4.3%, n =  3), 
and disease progression (4.3%, n = 3). Sixty-three deaths 
were reported: 10 (83.3%) in the 140  mg/day group and 
53 (91.4%) in the 100  mg/day group. Deaths were attrib-
uted primarily to progressive disease. Grade 5 AEs were 
reported in 6 patients (8.6%) in the 100 mg/day group and 
no patients in the 140  mg/day group. Grade 5 AEs con-
sisted of disease progression (3 patients) and intracranial 
tumor hemorrhage, general physical health deterioration, 
and increased intracranial pressure with herniation (1 
patient each). None of these grade 5 AEs were assessed as 
related to study treatment.
Discussion
Additional therapies for patients with GBM whose disease 
has progressed while receiving antiangiogenic agents are 
needed. There is no standard of care for GBM patients who 
have progressed on bevacizumab,5,9,27,28 and there are only 
scant reports of responses or prolonged stable disease fol-
lowing progression while on other antiangiogenic agents.29 
This phase II trial examined the efficacy and safety of cabozan-
tinib in 70 patients with recurrent GBM who had progressed 
on prior antiangiogenic therapy. The study did not meet the 
predefined statistical target for success. Approximately two-
thirds of patients receiving cabozantinib had a reduction in 
tumor lesions and 50% of patients achieved stable disease as 
best response; however, the ORR was 4.3%, median PFS was 
2.3 months, and median OS was 4.6 months (95% CI, 3.0–
5.6 mo). These results are similar to the median PFS of 1.3 
months reported in a retrospective analysis of patients who 
received an alternative bevacizumab regimen after progress-
ing on bevacizumab9 and a separate retrospective pooled 
analysis that reported medians for PFS and OS of 2.8 months 
and 5.9 months, respectively, in patients who continued on 
bevacizumab after progression.27 Similarly, median PFS was 
approximately 1 month for dasatinib,30 rilotumumab,31 or 
sunitinib32 therapy in patients with recurrent GBM after pro-
gression on bevacizumab.
Reported AEs were similar to those observed with other 
antiangiogenic agents, including bevacizumab, cediranib, 
and pazopanib, in this patient population.5,6,10,11 Adverse 
events were managed with supportive care and dose 
reductions or interruptions, and the overall duration of 
treatment was >5 weeks. The rate of discontinuations due 
to AEs and the rate of grade 3/4 AEs were higher in the 
140 mg/day group than in the 100 mg/day group, although 
SAEs and dose reductions were similar in the 2 groups. 
Both higher and lower starting doses of cabozantinib have 
been used in other indications. A cabozantinib dose of 140 
mg/day has been used for the treatment of medullary thy-
roid cancer,33 while a lower dose of 60 mg/day has been 
used for advanced renal cell carcinoma.34
GBM may be one of the most comprehensive molecularly 
characterized solid tumors,35 but molecular evaluations after 
GBM progression are far less robust. Nonetheless, clinical 
and preclinical data implicate a number of possible mecha-
nisms of resistance with antiangiogenic therapies in GBM,36 
and MET activation has been established as one of the 
principal mechanisms,19 suggesting a need for multitarget 
Fig.  1 Best changes from baseline in IRF measurements of tumor lesions using modified RANO criteria in patients who had measurable 
disease at baseline and ≥1 postbaseline radiographic scan. Lines indicate the threshold for response and progression per RANO criteria, ≥50% 
decrease and ≥25% increase, respectively. Partial responses were confirmed in 1 patient in the 140 mg/day group and 2 patients in the 100 mg/
day group. *Confirmed partial response. †No prior bevacizumab therapy.
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inhibitors in this setting.37 While cabozantinib targets mul-
tiple oncogenic pathways (MET, VEGFR2, AXL, KIT, RET, 
TIE2, and FLT3),24,38 it appears to have only modest clinical 
activity in patients with progressive or recurrent GBM who 
have received prior antiangiogenic therapy. More promising 
activity was observed with cabozantinib in the subset of 152 
patients not previously treated with antiangiogenic therapy 
(ORR of 15% for the combined dosing cohorts and a median 
PFS of 3.7 months in both cohorts; see companion article 
by Wen et al). Overall, patient baseline characteristics were 
similar in the naive and antiangiogenic treated patients with 
the exception of prior therapies. Additional studies that 
include molecular characterization of disease may help to 
better characterize differences between naive and antiangio-
genic treated patients with GBM.
This was the first investigational trial utilizing an experi-
mental therapy in the treatment of patients with GBM who 
had progressed on prior antiangiogenic therapy. The popu-
lation of patients with GBM progressing on bevacizumab 
is an area of unmet need warranting further clinical inves-
tigation. Challenges in study design include how to bet-
ter define the study population (eg, prior antiangiogenic 
therapies used, prior response obtained) and how to best 
define a meaningful response (eg, ORR, PFS, survival).
Fig. 2 Kaplan–Meier estimates of (A) progression-free survival and (B) overall survival by dose group on the basis of central assessment of 
radiographic images.  
Circles = censored records.








Table 3 Treatment-emergent adverse events (TEAEs) reported in ≥15% of patients in the 100 mg group
Adverse Event* Patients, n (%)
140 mg/day (n = 12) 100 mg/day (n = 58)
All Grades Grade 3/4 All Grades Grade 3/4
Any  TEAE 12 (100.0) 12 (100.0) 58 (100.0) 42 (72.4)
Fatigue 8 (66.7) 3 (25.0) 44 (75.9) 12 (20.7)
Diarrhea 8 (66.7) 2 (16.7) 25 (43.1) 2 (3.4)
ALT increased 4 (33.3) 2 (16.7) 22 (37.9) 4 (6.9)
Headache 4 (33.3) 1 (8.3) 21 (36.2) 5 (8.6)
Nausea 5 (41.7) 0 20 (34.5) 0
Hypertension 6 (50.0) 2 (16.7) 19 (32.8) 4 (6.9)
Constipation 5 (41.7) 1 (8.3) 19 (32.8) 1 (1.7)
AST increased 5 (41.7) 2 (16.7) 16 (27.6) 3 (5.2)
Blood LDH increased 3 (25.0) 0 16 (27.6) 1 (1.7)
Dysphonia 5 (41.7) 0 15 (25.9) 0
Memory impairment 3 (25.0) 0 15 (25.9) 0
Convulsion 2 (16.7) 1 (8.3) 15 (25.9) 3 (5.2)
Proteinuria 5 (41.7) 0 14 (24.1) 2 (3.4)
Confusional state 3 (25.0) 0 14 (24.1) 5 (8.6)
Cognitive disorder 2 (16.7) 1 (8.3) 13 (22.4) 0
Decreased appetite 4 (33.3) 0 12 (20.7) 1 (1.7)
Gait disturbance 3 (25.0) 1 (8.3) 12 (20.7) 3 (5.2)
PPES 3 (25.0) 0 11 (19.0) 3 (5.2)
Rash 3 (25.0) 0 11 (19.0) 0
Depression 1 (8.3) 0 11 (19.0) 0
Speech disorder 1 (8.3) 1 (8.3) 10 (17.2) 4 (6.9)
Thrombocytopenia 0 0 9 (15.5) 5 (8.6)
Abbreviations : ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; LDH,  
lactate dehydrogenase; MedDRA, Medical Dictionary for Regulatory Activities; PPES, palmar-plantar erythrodysesthesia syndrome.
*MedDRA v. 15.0 Preferred Terms (converted to US spelling), CTCAE v. 3.0 grading.
Fig. 3 Average daily glucocorticoid dose up to last treatment date among patients who reported any glucocorticoid use at baseline.
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